The tumor suppressor protein p53 orchestrates cellular responses to a vast number of stresses, with DNA damage and oncogenic activation being some of the best described. The capacity of p53 to control cellular events such as cell cycle progression, DNA repair, and apoptosis, to mention some, has been mostly linked to its role as a transcription factor. However, how p53 integrates different signaling cascades to promote a particular pathway remains an open question. One way to broaden its capacity to respond to different stimuli is by the expression of isoforms that can modulate the activities of the full-length protein. One of these isoforms is p47 (p53/47, Δ40p53, p53ΔN40), an alternative translation initiation variant whose expression is specifically induced by the PERK kinase during the Unfolded Protein Response (UPR) following Endoplasmic Reticulum stress. Despite the increasing knowledge on the p53 pathway, its activity when the translation machinery is globally suppressed during the UPR remains poorly understood. Here, we focus on the expression of p47 and we propose that the alternative initiation of p53 mRNA translation offers a unique condition-dependent mechanism to differentiate p53 activity to control cell homeostasis during the UPR. We also discuss how the manipulation of these processes may influence cancer cell physiology in light of therapeutic approaches.

Biochemistry Molecular Biology Faculty of Science Universidad de la República Iguá 4225 Montevideo 11400 Uruguay

Department of Medical Biosciences Umeå University 90185 Umeå Sweden

ICCVS University of Gdańsk Science ul Wita Stwosza 63 80 308 Gdańsk Poland

INSERM U1162 27 rue Juliette Dodu 75010 Paris France

RECAMO Masaryk Memorial Cancer Institute Zluty kopec 7 656 53 Brno Czech Republic

Zobrazit více v PubMed

Vousden K.H., Lane D.P. p53 in health and disease. Nat. Rev. Mol. Cell Biol. 2007;8:275–283. doi: 10.1038/nrm2147. PubMed DOI

Bouaoun L., Sonkin D., Ardin M., Hollstein M., Byrnes G., Zavadil J., Olivier M. TP53 Variations in Human Cancers: New Lessons from the IARC TP53 Database and Genomics Data: Human Mutation. Hum. Mutat. 2016;37:865–876. doi: 10.1002/humu.23035. PubMed DOI

Kandoth C., McLellan M.D., Vandin F., Ye K., Niu B., Lu C., Xie M., Zhang Q., McMichael J.F., Wyczalkowski M.A., et al. Mutational landscape and significance across 12 major cancer types. Nature. 2013;502:333–339. doi: 10.1038/nature12634. PubMed DOI PMC

Petitjean A., Mathe E., Kato S., Ishioka C., Tavtigian S.V., Hainaut P., Olivier M. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: Lessons from recent developments in the IARC TP53 database. Hum. Mutat. 2007;28:622–629. doi: 10.1002/humu.20495. PubMed DOI

Malkin D., Li F.P., Strong L.C., Fraumeni J.F., Nelson C.E., Kim D.H., Kassel J., Gryka M.A., Bischoff F.Z., Tainsky M.A. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science. 1990;250:1233–1238. doi: 10.1126/science.1978757. PubMed DOI

Zhou R., Xu A., Gingold J., Strong L.C., Zhao R., Lee D.-F. Li-Fraumeni Syndrome Disease Model: A Platform to Develop Precision Cancer Therapy Targeting Oncogenic p53. Trends Pharmacol. Sci. 2017;38:908–927. doi: 10.1016/j.tips.2017.07.004. PubMed DOI PMC

Lane D.P. How to lose tumor suppression. Science. 2019;365:539–540. doi: 10.1126/science.aay4319. PubMed DOI

Lane D.P., Crawford L.V. T antigen is bound to a host protein in SV40-transformed cells. Nature. 1979;278:261–263. doi: 10.1038/278261a0. PubMed DOI

Linzer D.I., Levine A.J. Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell. 1979;17:43–52. doi: 10.1016/0092-8674(79)90293-9. PubMed DOI

Sarnow P., Ho Y.S., Williams J., Levine A.J. Adenovirus E1b-58kd tumor antigen and SV40 large tumor antigen are physically associated with the same 54 kd cellular protein in transformed cells. Cell. 1982;28:387–394. doi: 10.1016/0092-8674(82)90356-7. PubMed DOI

Scheffner M., Werness B.A., Huibregtse J.M., Levine A.J., Howley P.M. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell. 1990;63:1129–1136. doi: 10.1016/0092-8674(90)90409-8. PubMed DOI

Werness B.A., Levine A.J., Howley P.M. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science. 1990;248:76–79. doi: 10.1126/science.2157286. PubMed DOI

Momand J., Zambetti G.P., Olson D.C., George D., Levine A.J. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell. 1992;69:1237–1245. doi: 10.1016/0092-8674(92)90644-R. PubMed DOI

Shvarts A., Steegenga W.T., Riteco N., van Laar T., Dekker P., Bazuine M., van Ham R.C., van der Houven van Oordt W., Hateboer G., van der Eb A.J., et al. MDMX: A novel p53-binding protein with some functional properties of MDM2. EMBO J. 1996;15:5349–5357. doi: 10.1002/j.1460-2075.1996.tb00919.x. PubMed DOI PMC

Kussie P.H., Gorina S., Marechal V., Elenbaas B., Moreau J., Levine A.J., Pavletich N.P. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science. 1996;274:948–953. doi: 10.1126/science.274.5289.948. PubMed DOI

Wade M., Li Y.-C., Wahl G.M. MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nat. Rev. Cancer. 2013;13:83–96. doi: 10.1038/nrc3430. PubMed DOI PMC

Fang S., Jensen J.P., Ludwig R.L., Vousden K.H., Weissman A.M. Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53. J. Biol. Chem. 2000;275:8945–8951. doi: 10.1074/jbc.275.12.8945. PubMed DOI

Nicolai S., Rossi A., Di Daniele N., Melino G., Annicchiarico-Petruzzelli M., Raschellà G. DNA repair and aging: The impact of the p53 family. Aging (Albany NY) 2015;7:1050–1065. doi: 10.18632/aging.100858. PubMed DOI PMC

Serrano M.A., Li Z., Dangeti M., Musich P.R., Patrick S., Roginskaya M., Cartwright B., Zou Y. DNA-PK, ATM and ATR collaboratively regulate p53-RPA interaction to facilitate homologous recombination DNA repair. Oncogene. 2013;32:2452–2462. doi: 10.1038/onc.2012.257. PubMed DOI PMC

el-Deiry W.S., Harper J.W., O’Connor P.M., Velculescu V.E., Canman C.E., Jackman J., Pietenpol J.A., Burrell M., Hill D.E., Wang Y. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res. 1994;54:1169–1174. PubMed

Kastan M.B., Zhan Q., el-Deiry W.S., Carrier F., Jacks T., Walsh W.V., Plunkett B.S., Vogelstein B., Fornace A.J. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell. 1992;71:587–597. doi: 10.1016/0092-8674(92)90593-2. PubMed DOI

Lanigan F., Geraghty J.G., Bracken A.P. Transcriptional regulation of cellular senescence. Oncogene. 2011;30:2901–2911. doi: 10.1038/onc.2011.34. PubMed DOI

Miyashita T., Reed J.C. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell. 1995;80:293–299. PubMed

Miyashita T., Harigai M., Hanada M., Reed J.C. Identification of a p53-dependent negative response element in the bcl-2 gene. Cancer Res. 1994;54:3131–3135. PubMed

Efeyan A., Collado M., Velasco-Miguel S., Serrano M. Genetic dissection of the role of p21Cip1/Waf1 in p53-mediated tumour suppression. Oncogene. 2007;26:1645–1649. doi: 10.1038/sj.onc.1209972. PubMed DOI

Barak Y., Juven T., Haffner R., Oren M. mdm2 expression is induced by wild type p53 activity. EMBO J. 1993;12:461–468. doi: 10.1002/j.1460-2075.1993.tb05678.x. PubMed DOI PMC

Candeias M.M., Malbert-Colas L., Powell D.J., Daskalogianni C., Maslon M.M., Naski N., Bourougaa K., Calvo F., Fåhraeus R. P53 mRNA controls p53 activity by managing Mdm2 functions. Nat. Cell Biol. 2008;10:1098–1105. doi: 10.1038/ncb1770. PubMed DOI

Malbert-Colas L., Ponnuswamy A., Olivares-Illana V., Tournillon A.-S., Naski N., Fåhraeus R. HDMX folds the nascent p53 mRNA following activation by the ATM kinase. Mol. Cell. 2014;54:500–511. doi: 10.1016/j.molcel.2014.02.035. PubMed DOI

Gajjar M., Candeias M.M., Malbert-Colas L., Mazars A., Fujita J., Olivares-Illana V., Fåhraeus R. The p53 mRNA-Mdm2 interaction controls Mdm2 nuclear trafficking and is required for p53 activation following DNA damage. Cancer Cell. 2012;21:25–35. doi: 10.1016/j.ccr.2011.11.016. PubMed DOI

López I., Tournillon A.-S., Nylander K., Fåhraeus R. p53-mediated control of gene expression via mRNA translation during Endoplasmic Reticulum stress. Cell Cycle. 2015;14:3373–3378. doi: 10.1080/15384101.2015.1090066. PubMed DOI PMC

Mlynarczyk C., Fåhraeus R. Endoplasmic reticulum stress sensitizes cells to DNA damage-induced apoptosis through p53-dependent suppression of p21(CDKN1A) Nat. Commun. 2014;5:5067. doi: 10.1038/ncomms6067. PubMed DOI

Chong W.C., Shastri M.D., Eri R. Endoplasmic Reticulum Stress and Oxidative Stress: A Vicious Nexus Implicated in Bowel Disease Pathophysiology. Int. J. Mol. Sci. 2017;18:771. doi: 10.3390/ijms18040771. PubMed DOI PMC

Hetz C., Chevet E., Harding H.P. Targeting the unfolded protein response in disease. Nat. Rev. Drug Discov. 2013;12:703–719. doi: 10.1038/nrd3976. PubMed DOI

Zhao L., Ackerman S.L. Endoplasmic reticulum stress in health and disease. Curr. Opin. Cell Biol. 2006;18:444–452. doi: 10.1016/j.ceb.2006.06.005. PubMed DOI

Hetz C., Chevet E., Oakes S.A. Proteostasis control by the unfolded protein response. Nat. Cell Biol. 2015;17:829–838. doi: 10.1038/ncb3184. PubMed DOI PMC

Limia C.M., Sauzay C., Urra H., Hetz C., Chevet E., Avril T. Emerging Roles of the Endoplasmic Reticulum Associated Unfolded Protein Response in Cancer Cell Migration and Invasion. Cancers. 2019;11:631. doi: 10.3390/cancers11050631. PubMed DOI PMC

Nam S.M., Jeon Y.J. Proteostasis in The Endoplasmic Reticulum: Road to Cure. Cancers. 2019;11:1793. doi: 10.3390/cancers11111793. PubMed DOI PMC

Bertolotti A., Zhang Y., Hendershot L.M., Harding H.P., Ron D. Dynamic interaction of BiP and ER stress transducers in the unfolded-protein response. Nat. Cell Biol. 2000;2:326–332. doi: 10.1038/35014014. PubMed DOI

D’Orazi G., Cirone M. Mutant p53 and Cellular Stress Pathways: A Criminal Alliance That Promotes Cancer Progression. Cancers. 2019;11:614. doi: 10.3390/cancers11050614. PubMed DOI PMC

Lee A.S. Glucose-regulated proteins in cancer: Molecular mechanisms and therapeutic potential. Nat. Rev. Cancer. 2014;14:263–276. doi: 10.1038/nrc3701. PubMed DOI PMC

Luo B., Lee A.S. The critical roles of endoplasmic reticulum chaperones and unfolded protein response in tumorigenesis and anticancer therapies. Oncogene. 2013;32:805–818. doi: 10.1038/onc.2012.130. PubMed DOI PMC

Ma Y., Hendershot L.M. The role of the unfolded protein response in tumour development: Friend or foe? Nat. Rev. Cancer. 2004;4:966–977. doi: 10.1038/nrc1505. PubMed DOI

Urra H., Dufey E., Lisbona F., Rojas-Rivera D., Hetz C. When ER stress reaches a dead end. Biochim. Biophys. Acta. 2013;1833:3507–3517. doi: 10.1016/j.bbamcr.2013.07.024. PubMed DOI

Crawford L.J., Walker B., Irvine A.E. Proteasome inhibitors in cancer therapy. J. Cell Commun. Signal. 2011;5:101–110. doi: 10.1007/s12079-011-0121-7. PubMed DOI PMC

Manasanch E.E., Orlowski R.Z. Proteasome inhibitors in cancer therapy. Nat. Rev. Clin. Oncol. 2017;14:417–433. doi: 10.1038/nrclinonc.2016.206. PubMed DOI PMC

Li J., Lee B., Lee A.S. Endoplasmic reticulum stress-induced apoptosis: Multiple pathways and activation of p53-up-regulated modulator of apoptosis (PUMA) and NOXA by p53. J. Biol. Chem. 2006;281:7260–7270. doi: 10.1074/jbc.M509868200. PubMed DOI

Zhang F., Hamanaka R.B., Bobrovnikova-Marjon E., Gordan J.D., Dai M.-S., Lu H., Simon M.C., Diehl J.A. Ribosomal stress couples the unfolded protein response to p53-dependent cell cycle arrest. J. Biol. Chem. 2006;281:30036–30045. doi: 10.1074/jbc.M604674200. PubMed DOI

Jiang C.C., Lucas K., Avery-Kiejda K.A., Wade M., deBock C.E., Thorne R.F., Allen J., Hersey P., Zhang X.D. Up-regulation of Mcl-1 is critical for survival of human melanoma cells upon endoplasmic reticulum stress. Cancer Res. 2008;68:6708–6717. doi: 10.1158/0008-5472.CAN-08-0349. PubMed DOI

Kalouche G., Boucher C., Coste A., Debussche L., Orsini C., Baudouin C., Debeir T., Vigé X., Rostène W. Prostaglandin EP2 receptor signaling protects human trabecular meshwork cells from apoptosis induced by ER stress through down-regulation of p53. Biochim. Biophys. Acta. 2016;1863:2322–2332. doi: 10.1016/j.bbamcr.2016.06.008. PubMed DOI

Lin W.-C., Chuang Y.-C., Chang Y.-S., Lai M.-D., Teng Y.-N., Su I.-J., Wang C.C.C., Lee K.-H., Hung J.-H. Endoplasmic reticulum stress stimulates p53 expression through NF-κB activation. PLoS ONE. 2012;7:e39120. doi: 10.1371/journal.pone.0039120. PubMed DOI PMC

Han J., Back S.H., Hur J., Lin Y.-H., Gildersleeve R., Shan J., Yuan C.L., Krokowski D., Wang S., Hatzoglou M., et al. ER-stress-induced transcriptional regulation increases protein synthesis leading to cell death. Nat. Cell Biol. 2013;15:481–490. doi: 10.1038/ncb2738. PubMed DOI PMC

Baltzis D., Pluquet O., Papadakis A.I., Kazemi S., Qu L.-K., Koromilas A.E. The eIF2alpha kinases PERK and PKR activate glycogen synthase kinase 3 to promote the proteasomal degradation of p53. J. Biol. Chem. 2007;282:31675–31687. doi: 10.1074/jbc.M704491200. PubMed DOI

Qu L., Huang S., Baltzis D., Rivas-Estilla A.-M., Pluquet O., Hatzoglou M., Koumenis C., Taya Y., Yoshimura A., Koromilas A.E. Endoplasmic reticulum stress induces p53 cytoplasmic localization and prevents p53-dependent apoptosis by a pathway involving glycogen synthase kinase-3beta. Genes Dev. 2004;18:261–277. doi: 10.1101/gad.1165804. PubMed DOI PMC

Pluquet O., Qu L.-K., Baltzis D., Koromilas A.E. Endoplasmic reticulum stress accelerates p53 degradation by the cooperative actions of Hdm2 and glycogen synthase kinase 3beta. Mol. Cell. Biol. 2005;25:9392–9405. doi: 10.1128/MCB.25.21.9392-9405.2005. PubMed DOI PMC

Liu D.-C., Eagleman D.E., Tsai N.-P. Novel roles of ER stress in repressing neural activity and seizures through Mdm2- and p53-dependent protein translation. PLoS Genet. 2019;15:e1008364. doi: 10.1371/journal.pgen.1008364. PubMed DOI PMC

Morito D., Nagata K. Pathogenic Hijacking of ER-Associated Degradation: Is ERAD Flexible? Mol. Cell. 2015;59:335–344. doi: 10.1016/j.molcel.2015.06.010. PubMed DOI

Yamasaki S., Yagishita N., Sasaki T., Nakazawa M., Kato Y., Yamadera T., Bae E., Toriyama S., Ikeda R., Zhang L., et al. Cytoplasmic destruction of p53 by the endoplasmic reticulum-resident ubiquitin ligase “Synoviolin”. EMBO J. 2007;26:113–122. doi: 10.1038/sj.emboj.7601490. PubMed DOI PMC

Bourougaa K., Naski N., Boularan C., Mlynarczyk C., Candeias M.M., Marullo S., Fåhraeus R. Endoplasmic reticulum stress induces G2 cell-cycle arrest via mRNA translation of the p53 isoform p53/47. Mol. Cell. 2010;38:78–88. doi: 10.1016/j.molcel.2010.01.041. PubMed DOI

Candeias M.M., Powell D.J., Roubalova E., Apcher S., Bourougaa K., Vojtesek B., Bruzzoni-Giovanelli H., Fåhraeus R. Expression of p53 and p53/47 are controlled by alternative mechanisms of messenger RNA translation initiation. Oncogene. 2006;25:6936–6947. doi: 10.1038/sj.onc.1209996. PubMed DOI

Courtois S., Verhaegh G., North S., Luciani M.-G., Lassus P., Hibner U., Oren M., Hainaut P. DeltaN-p53, a natural isoform of p53 lacking the first transactivation domain, counteracts growth suppression by wild-type p53. Oncogene. 2002;21:6722–6728. doi: 10.1038/sj.onc.1205874. PubMed DOI

Ray P.S., Grover R., Das S. Two internal ribosome entry sites mediate the translation of p53 isoforms. EMBO Rep. 2006;7:404–410. doi: 10.1038/sj.embor.7400623. PubMed DOI PMC

Yin Y., Stephen C.W., Luciani M.G., Fåhraeus R. p53 Stability and activity is regulated by Mdm2-mediated induction of alternative p53 translation products. Nat. Cell Biol. 2002;4:462–467. doi: 10.1038/ncb801. PubMed DOI

Ohki R., Kawase T., Ohta T., Ichikawa H., Taya Y. Dissecting functional roles of p53 N-terminal transactivation domains by microarray expression analysis. Cancer Sci. 2007;98:189–200. doi: 10.1111/j.1349-7006.2006.00375.x. PubMed DOI PMC

Joruiz S.M., Bourdon J.-C. p53 Isoforms: Key Regulators of the Cell Fate Decision. Cold Spring Harb. Perspect. Med. 2016;6:a026039. doi: 10.1101/cshperspect.a026039. PubMed DOI PMC

Bourdon J.-C., Fernandes K., Murray-Zmijewski F., Liu G., Diot A., Xirodimas D.P., Saville M.K., Lane D.P. p53 isoforms can regulate p53 transcriptional activity. Genes Dev. 2005;19:2122–2137. doi: 10.1101/gad.1339905. PubMed DOI PMC

Khoury M.P., Bourdon J.-C. p53 Isoforms: An Intracellular Microprocessor? Genes Cancer. 2011;2:453–465. doi: 10.1177/1947601911408893. PubMed DOI PMC

Baird S.D., Turcotte M., Korneluk R.G., Holcik M. Searching for IRES. RNA. 2006;12:1755–1785. doi: 10.1261/rna.157806. PubMed DOI PMC

Holcik M., Sonenberg N. Translational control in stress and apoptosis. Nat. Rev. Mol. Cell Biol. 2005;6:318–327. doi: 10.1038/nrm1618. PubMed DOI

Yang D.-Q., Halaby M.-J., Zhang Y. The identification of an internal ribosomal entry site in the 5′-untranslated region of p53 mRNA provides a novel mechanism for the regulation of its translation following DNA damage. Oncogene. 2006;25:4613–4619. doi: 10.1038/sj.onc.1209483. PubMed DOI

Haronikova L., Olivares-Illana V., Wang L., Karakostis K., Chen S., Fåhraeus R. The p53 mRNA: An integral part of the cellular stress response. Nucleic Acids Res. 2019;47:3257–3271. doi: 10.1093/nar/gkz124. PubMed DOI PMC

Karakostis K., Fåhraeus R. Shaping the regulation of the p53 mRNA tumour suppressor: The co-evolution of genetic signatures. BMC Cancer. 2019;19:915. doi: 10.1186/s12885-019-6118-y. PubMed DOI PMC

Karakostis K., Vadivel Gnanasundram S., López I., Thermou A., Wang L., Nylander K., Olivares-Illana V., Fåhraeus R. A single synonymous mutation determines the phosphorylation and stability of the nascent protein. J. Mol. Cell Biol. 2019;11:187–199. doi: 10.1093/jmcb/mjy049. PubMed DOI PMC

Pyronnet S., Pradayrol L., Sonenberg N. A cell cycle-dependent internal ribosome entry site. Mol. Cell. 2000;5:607–616. doi: 10.1016/S1097-2765(00)80240-3. PubMed DOI

Sivan G., Elroy-Stein O. Regulation of mRNA Translation during cellular division. Cell Cycle. 2008;7:741–744. doi: 10.4161/cc.7.6.5596. PubMed DOI

Cornelis S., Bruynooghe Y., Denecker G., Van Huffel S., Tinton S., Beyaert R. Identification and characterization of a novel cell cycle-regulated internal ribosome entry site. Mol. Cell. 2000;5:597–605. doi: 10.1016/S1097-2765(00)80239-7. PubMed DOI

Fernandez J., Bode B., Koromilas A., Diehl J.A., Krukovets I., Snider M.D., Hatzoglou M. Translation mediated by the internal ribosome entry site of the cat-1 mRNA is regulated by glucose availability in a PERK kinase-dependent manner. J. Biol. Chem. 2002;277:11780–11787. doi: 10.1074/jbc.M110778200. PubMed DOI

Vattem K.M., Wek R.C. Reinitiation involving upstream ORFs regulates ATF4 mRNA translation in mammalian cells. Proc. Natl. Acad. Sci. USA. 2004;101:11269–11274. doi: 10.1073/pnas.0400541101. PubMed DOI PMC

Lavigueur A., Maltby V., Mock D., Rossant J., Pawson T., Bernstein A. High incidence of lung, bone, and lymphoid tumors in transgenic mice overexpressing mutant alleles of the p53 oncogene. Mol. Cell. Biol. 1989;9:3982–3991. doi: 10.1128/MCB.9.9.3982. PubMed DOI PMC

Melis J.P.M., Hoogervorst E.M., van Oostrom C.T.M., Zwart E., Breit T.M., Pennings J.L.A., de Vries A., van Steeg H. Genotoxic exposure: Novel cause of selection for a functional ΔN-p53 isoform. Oncogene. 2011;30:1764–1772. doi: 10.1038/onc.2010.552. PubMed DOI

Powell D.J., Hrstka R., Candeias M., Bourougaa K., Vojtesek B., Fåhraeus R. Stress-dependent changes in the properties of p53 complexes by the alternative translation product p53/47. Cell Cycle. 2008;7:950–959. doi: 10.4161/cc.7.7.5626. PubMed DOI

Phang B.H., Othman R., Bougeard G., Chia R.H., Frebourg T., Tang C.L., Cheah P.Y., Sabapathy K. Amino-terminal p53 mutations lead to expression of apoptosis proficient p47 and prognosticate better survival, but predispose to tumorigenesis. Proc. Natl. Acad. Sci. USA. 2015;112:E6349–E6358. doi: 10.1073/pnas.1510043112. PubMed DOI PMC

Ghosh A., Stewart D., Matlashewski G. Regulation of human p53 activity and cell localization by alternative splicing. Mol. Cell. Biol. 2004;24:7987–7997. doi: 10.1128/MCB.24.18.7987-7997.2004. PubMed DOI PMC

Tyner S.D., Venkatachalam S., Choi J., Jones S., Ghebranious N., Igelmann H., Lu X., Soron G., Cooper B., Brayton C., et al. p53 mutant mice that display early ageing-associated phenotypes. Nature. 2002;415:45–53. doi: 10.1038/415045a. PubMed DOI

Maier B., Gluba W., Bernier B., Turner T., Mohammad K., Guise T., Sutherland A., Thorner M., Scrable H. Modulation of mammalian life span by the short isoform of p53. Genes Dev. 2004;18:306–319. doi: 10.1101/gad.1162404. PubMed DOI PMC

Migliaccio E., Giorgio M., Pelicci P.G. Apoptosis and aging: Role of p66Shc redox protein. Antioxid. Redox Signal. 2006;8:600–608. doi: 10.1089/ars.2006.8.600. PubMed DOI

Gambino V., De Michele G., Venezia O., Migliaccio P., Dall’Olio V., Bernard L., Minardi S.P., Della Fazia M.A., Bartoli D., Servillo G., et al. Oxidative stress activates a specific p53 transcriptional response that regulates cellular senescence and aging. Aging Cell. 2013;12:435–445. doi: 10.1111/acel.12060. PubMed DOI PMC

Pehar M., Ko M.H., Li M., Scrable H., Puglielli L. P44, the “longevity-assurance” isoform of P53, regulates tau phosphorylation and is activated in an age-dependent fashion. Aging Cell. 2014;13:449–456. doi: 10.1111/acel.12192. PubMed DOI PMC

Nalivaeva N.N., Turner A.J. The amyloid precursor protein: A biochemical enigma in brain development, function and disease. FEBS Lett. 2013;587:2046–2054. doi: 10.1016/j.febslet.2013.05.010. PubMed DOI

Li M., Pehar M., Liu Y., Bhattacharyya A., Zhang S.-C., O’Riordan K.J., Burger C., D’Adamio L., Puglielli L. The amyloid precursor protein (APP) intracellular domain regulates translation of p44, a short isoform of p53, through an IRES-dependent mechanism. Neurobiol. Aging. 2015;36:2725–2736. doi: 10.1016/j.neurobiolaging.2015.06.021. PubMed DOI PMC

Ungewitter E., Scrable H. Delta40p53 controls the switch from pluripotency to differentiation by regulating IGF signaling in ESCs. Genes Dev. 2010;24:2408–2419. doi: 10.1101/gad.1987810. PubMed DOI PMC

Takahashi R., Giannini C., Sarkaria J.N., Schroeder M., Rogers J., Mastroeni D., Scrable H. p53 isoform profiling in glioblastoma and injured brain. Oncogene. 2013;32:3165–3174. doi: 10.1038/onc.2012.322. PubMed DOI PMC

Singh S.K., Hawkins C., Clarke I.D., Squire J.A., Bayani J., Hide T., Henkelman R.M., Cusimano M.D., Dirks P.B. Identification of human brain tumour initiating cells. Nature. 2004;432:396–401. doi: 10.1038/nature03128. PubMed DOI

Avery-Kiejda K.A., Zhang X.D., Adams L.J., Scott R.J., Vojtesek B., Lane D.P., Hersey P. Small molecular weight variants of p53 are expressed in human melanoma cells and are induced by the DNA-damaging agent cisplatin. Clin. Cancer Res. 2008;14:1659–1668. doi: 10.1158/1078-0432.CCR-07-1422. PubMed DOI

Hofstetter G., Berger A., Schuster E., Wolf A., Hager G., Vergote I., Cadron I., Sehouli J., Braicu E.I., Mahner S., et al. Δ133p53 is an independent prognostic marker in p53 mutant advanced serous ovarian cancer. Br. J. Cancer. 2011;105:1593–1599. doi: 10.1038/bjc.2011.433. PubMed DOI PMC

Vieler M., Sanyal S. p53 Isoforms and Their Implications in Cancer. Cancers. 2018;10:288. doi: 10.3390/cancers10090288. PubMed DOI PMC

Mihailidou C., Chatzistamou I., Papavassiliou A.G., Kiaris H. Improvement of chemotherapeutic drug efficacy by endoplasmic reticulum stress. Endocr. Relat. Cancer. 2015;22:229–238. doi: 10.1530/ERC-15-0019. PubMed DOI

Chan T.A., Hermeking H., Lengauer C., Kinzler K.W., Vogelstein B. 14-3-3Sigma is required to prevent mitotic catastrophe after DNA damage. Nature. 1999;401:616–620. doi: 10.1038/44188. PubMed DOI

López I., Tournillon A.-S., Prado Martins R., Karakostis K., Malbert-Colas L., Nylander K., Fåhraeus R. p53-mediated suppression of BiP triggers BIK-induced apoptosis during prolonged endoplasmic reticulum stress. Cell Death Differ. 2017;24:1717–1729. doi: 10.1038/cdd.2017.96. PubMed DOI PMC

Fu Y., Li J., Lee A.S. GRP78/BiP inhibits endoplasmic reticulum BIK and protects human breast cancer cells against estrogen starvation-induced apoptosis. Cancer Res. 2007;67:3734–3740. doi: 10.1158/0008-5472.CAN-06-4594. PubMed DOI

Kern J., Untergasser G., Zenzmaier C., Sarg B., Gastl G., Gunsilius E., Steurer M. GRP-78 secreted by tumor cells blocks the antiangiogenic activity of bortezomib. Blood. 2009;114:3960–3967. doi: 10.1182/blood-2009-03-209668. PubMed DOI

Luo S., Mao C., Lee B., Lee A.S. GRP78/BiP is required for cell proliferation and protecting the inner cell mass from apoptosis during early mouse embryonic development. Mol. Cell. Biol. 2006;26:5688–5697. doi: 10.1128/MCB.00779-06. PubMed DOI PMC

Rao R.V., Peel A., Logvinova A., del Rio G., Hermel E., Yokota T., Goldsmith P.C., Ellerby L.M., Ellerby H.M., Bredesen D.E. Coupling endoplasmic reticulum stress to the cell death program: Role of the ER chaperone GRP78. FEBS Lett. 2002;514:122–128. doi: 10.1016/S0014-5793(02)02289-5. PubMed DOI PMC

Reddy R.K., Mao C., Baumeister P., Austin R.C., Kaufman R.J., Lee A.S. Endoplasmic reticulum chaperone protein GRP78 protects cells from apoptosis induced by topoisomerase inhibitors: Role of ATP binding site in suppression of caspase-7 activation. J. Biol. Chem. 2003;278:20915–20924. doi: 10.1074/jbc.M212328200. PubMed DOI

Sakitani K., Hirata Y., Hikiba Y., Hayakawa Y., Ihara S., Suzuki H., Suzuki N., Serizawa T., Kinoshita H., Sakamoto K., et al. Inhibition of autophagy exerts anti-colon cancer effects via apoptosis induced by p53 activation and ER stress. BMC Cancer. 2015;15:795. doi: 10.1186/s12885-015-1789-5. PubMed DOI PMC

Wang M., Ye R., Barron E., Baumeister P., Mao C., Luo S., Fu Y., Luo B., Dubeau L., Hinton D.R., et al. Essential role of the unfolded protein response regulator GRP78/BiP in protection from neuronal apoptosis. Cell Death Differ. 2010;17:488–498. doi: 10.1038/cdd.2009.144. PubMed DOI PMC

Zhou H., Zhang Y., Fu Y., Chan L., Lee A.S. Novel mechanism of anti-apoptotic function of 78-kDa glucose-regulated protein (GRP78): Endocrine resistance factor in breast cancer, through release of B-cell lymphoma 2 (BCL-2) from BCL-2-interacting killer (BIK) J. Biol. Chem. 2011;286:25687–25696. doi: 10.1074/jbc.M110.212944. PubMed DOI PMC

Pyrko P., Schönthal A.H., Hofman F.M., Chen T.C., Lee A.S. The unfolded protein response regulator GRP78/BiP as a novel target for increasing chemosensitivity in malignant gliomas. Cancer Res. 2007;67:9809–9816. doi: 10.1158/0008-5472.CAN-07-0625. PubMed DOI

Pootrakul L., Datar R.H., Shi S.-R., Cai J., Hawes D., Groshen S.G., Lee A.S., Cote R.J. Expression of stress response protein Grp78 is associated with the development of castration-resistant prostate cancer. Clin. Cancer Res. 2006;12:5987–5993. doi: 10.1158/1078-0432.CCR-06-0133. PubMed DOI

Zhuang L., Scolyer R.A., Lee C.S., McCarthy S.W., Cooper W.A., Zhang X.D., Thompson J.F., Hersey P. Expression of glucose-regulated stress protein GRP78 is related to progression of melanoma. Histopathology. 2009;54:462–470. doi: 10.1111/j.1365-2559.2009.03242.x. PubMed DOI

Wu M.-J., Jan C.-I., Tsay Y.-G., Yu Y.-H., Huang C.-Y., Lin S.-C., Liu C.-J., Chen Y.-S., Lo J.-F., Yu C.-C. Elimination of head and neck cancer initiating cells through targeting glucose regulated protein78 signaling. Mol. Cancer. 2010;9:283. doi: 10.1186/1476-4598-9-283. PubMed DOI PMC

Namba T., Chu K., Kodama R., Byun S., Yoon K.W., Hiraki M., Mandinova A., Lee S.W. Loss of p53 enhances the function of the endoplasmic reticulum through activation of the IRE1α/XBP1 pathway. Oncotarget. 2015;6:19990–20001. doi: 10.18632/oncotarget.4598. PubMed DOI PMC

Kasteri J., Das D., Zhong X., Persaud L., Francis A., Muharam H., Sauane M. Translation Control by p53. Cancers. 2018;10:133. doi: 10.3390/cancers10050133. PubMed DOI PMC

Loayza-Puch F., Drost J., Rooijers K., Lopes R., Elkon R., Agami R. p53 induces transcriptional and translational programs to suppress cell proliferation and growth. Genome Biol. 2013;14:R32. doi: 10.1186/gb-2013-14-4-r32. PubMed DOI PMC

Zaccara S., Tebaldi T., Pederiva C., Ciribilli Y., Bisio A., Inga A. p53-directed translational control can shape and expand the universe of p53 target genes. Cell Death Differ. 2014;21:1522–1534. doi: 10.1038/cdd.2014.79. PubMed DOI PMC

Hudson W.H., Ortlund E.A. The structure, function and evolution of proteins that bind DNA and RNA. Nat. Rev. Mol. Cell Biol. 2014;15:749–760. doi: 10.1038/nrm3884. PubMed DOI PMC

Galy B., Créancier L., Prado-Lourenço L., Prats A.C., Prats H. p53 directs conformational change and translation initiation blockade of human fibroblast growth factor 2 mRNA. Oncogene. 2001;20:4613–4620. doi: 10.1038/sj.onc.1204630. PubMed DOI

Galy B., Créancier L., Zanibellato C., Prats A.C., Prats H. Tumour suppressor p53 inhibits human fibroblast growth factor 2 expression by a post-transcriptional mechanism. Oncogene. 2001;20:1669–1677. doi: 10.1038/sj.onc.1204271. PubMed DOI

Miller S.J., Suthiphongchai T., Zambetti G.P., Ewen M.E. p53 binds selectively to the 5’ untranslated region of cdk4, an RNA element necessary and sufficient for transforming growth factor beta- and p53-mediated translational inhibition of cdk4. Mol. Cell. Biol. 2000;20:8420–8431. doi: 10.1128/MCB.20.22.8420-8431.2000. PubMed DOI PMC

Mosner J., Mummenbrauer T., Bauer C., Sczakiel G., Grosse F., Deppert W. Negative feedback regulation of wild-type p53 biosynthesis. EMBO J. 1995;14:4442–4449. doi: 10.1002/j.1460-2075.1995.tb00123.x. PubMed DOI PMC

Oberosler P., Hloch P., Ramsperger U., Stahl H. p53-catalyzed annealing of complementary single-stranded nucleic acids. EMBO J. 1993;12:2389–2396. doi: 10.1002/j.1460-2075.1993.tb05893.x. PubMed DOI PMC

Shetty S., Shetty P., Idell S., Velusamy T., Bhandary Y.P., Shetty R.S. Regulation of plasminogen activator inhibitor-1 expression by tumor suppressor protein p53. J. Biol. Chem. 2008;283:19570–19580. doi: 10.1074/jbc.M710268200. PubMed DOI PMC

Tournillon A.-S., López I., Malbert-Colas L., Findakly S., Naski N., Olivares-Illana V., Karakostis K., Vojtesek B., Nylander K., Fåhraeus R. p53 binds the mdmx mRNA and controls its translation. Oncogene. 2017;36:723–730. doi: 10.1038/onc.2016.236. PubMed DOI

Riley K.J.-L., Maher L.J. p53 RNA interactions: New clues in an old mystery. RNA. 2007;13:1825–1833. doi: 10.1261/rna.673407. PubMed DOI PMC

Sicari D., Fantuz M., Bellazzo A., Valentino E., Apollonio M., Pontisso I., Di Cristino F., Dal Ferro M., Bicciato S., Del Sal G., et al. Mutant p53 improves cancer cells’ resistance to endoplasmic reticulum stress by sustaining activation of the UPR regulator ATF6. Oncogene. 2019;38:6184–6195. doi: 10.1038/s41388-019-0878-3. PubMed DOI

Dai L., He G., Zhang K., Guan X., Wang Y., Zhang B. Trichostatin A induces p53-dependent endoplasmic reticulum stress in human colon cancer cells. Oncol. Lett. 2019;17:660–667. doi: 10.3892/ol.2018.9641. PubMed DOI PMC

Li D., Marchenko N.D., Moll U.M. SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis. Cell Death Differ. 2011;18:1904–1913. doi: 10.1038/cdd.2011.71. PubMed DOI PMC

Boettcher S., Miller P.G., Sharma R., McConkey M., Leventhal M., Krivtsov A.V., Giacomelli A.O., Wong W., Kim J., Chao S., et al. A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies. Science. 2019;365:599–604. doi: 10.1126/science.aax3649. PubMed DOI PMC

Roeten M.S.F., Cloos J., Jansen G. Positioning of proteasome inhibitors in therapy of solid malignancies. Cancer Chemother. Pharmacol. 2018;81:227–243. doi: 10.1007/s00280-017-3489-0. PubMed DOI PMC

Vaziri S.A.J., Grabowski D.R., Hill J., Rybicki L.R., Burk R., Bukowski R.M., Ganapathi M.K., Ganapathi R. Inhibition of proteasome activity by bortezomib in renal cancer cells is p53 dependent and VHL independent. Anticancer Res. 2009;29:2961–2969. PubMed PMC

Ding W.-X., Ni H.-M., Chen X., Yu J., Zhang L., Yin X.-M. A coordinated action of Bax, PUMA, and p53 promotes MG132-induced mitochondria activation and apoptosis in colon cancer cells. Mol. Cancer Ther. 2007;6:1062–1069. doi: 10.1158/1535-7163.MCT-06-0541. PubMed DOI

MacLaren A.P., Chapman R.S., Wyllie A.H., Watson C.J. p53-dependent apoptosis induced by proteasome inhibition in mammary epithelial cells. Cell Death Differ. 2001;8:210–218. doi: 10.1038/sj.cdd.4400801. PubMed DOI

Williams S.A., McConkey D.J. The proteasome inhibitor bortezomib stabilizes a novel active form of p53 in human LNCaP-Pro5 prostate cancer cells. Cancer Res. 2003;63:7338–7344. PubMed

Lopes U.G., Erhardt P., Yao R., Cooper G.M. p53-dependent Induction of Apoptosis by Proteasome Inhibitors. J. Biol. Chem. 1997;272:12893–12896. doi: 10.1074/jbc.272.20.12893. PubMed DOI

Qin J.-Z., Ziffra J., Stennett L., Bodner B., Bonish B.K., Chaturvedi V., Bennett F., Pollock P.M., Trent J.M., Hendrix M.J.C., et al. Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells. Cancer Res. 2005;65:6282–6293. doi: 10.1158/0008-5472.CAN-05-0676. PubMed DOI

The p53 endoplasmic reticulum stress-response pathway evolved in humans but not in mice via PERK-regulated p53 mRNA structures